Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline


Find out about our commitment to IBD patients

10 million people worldwide suffer from Inflammatory Bowel Disease

Over 10 million people worldwide suffer from Inflammatory Bowel Disease (IBD).2 The specific cause of IBD, which includes both Ulcerative Colitis and Crohn’s disease, still remains unknown.1,4 Although not completely understood, IBD pathology appears to involve a combination of genetic, microbiota and environmental factors.4 Maintenance of remission of IBD remains an unsolved challenge.2

Each IBD patient is unique, requiring tailored strategies to achieve and sustain remission.2,5 50–80% of IBD patients suffer a lifetime course of unpredictable flare-ups and remission.1,2 Lack of compliance and self-monitoring knowledge can lead to loss of IBD remission and delayed treatment adjustments.2,6,7 Despite treatment, mild-to-moderate IBD patients consistently trend towards slow disease worsening, leading to increasingly aggressive therapeutic measures.2,5

Ferring remains committed to the unmet needs of IBD-patients, worldwide. We are pioneering a new era in gastroenterology, by collaborating with partners to research the next generation of microbiome treatments.8 The data collected will support future research and development in areas of high unmet need, including inflammatory bowel disease.8

We are committed to deepening our understanding of the role of the human microbiome in the development of the disease, to address the unmet needs of patients.

On World IBD Day, Ferring continues to demonstrate its commitment to addressing the unmet needs of IBD patients worldwide. Want to find out more? Follow Ferring on Twitter and Facebook to learn more about IBD so that we can increase awareness and improve disease management for IBD patients around the world. For IBD information and support please visit: www.guts4life.com.

1. Bannaga AS and Selinger CP. Clin Exp Gastroenterol. 2015;23;8:111–7.
2. Actis GC and Pellicano R. World J Gastrointest Pharmacol Ther. 2017;8(2):114–9.
3. Hammer T et al., J Crohn’s Colitis 2016;10(8):934–942.
4. Derwa Y et al. Aliment Pharmacol Ther. 2017;46:389–400.
5. Harbord M et al. J Crohns Colitis. 2017;11(7):769–84.
6. Danese S et al. Intest Res. 2018;16(4):522–8.
7. Lorenzon G and D’Incà R. Gastrointest Cancer Res Ther. 2017;2(1):1017.
8. Ferring press release. Jan 22 2019. Saint-Prex, Switzerland.

Ferring Private Ltd.
168 Robinson Road
#13-01 Capital Tower  
068912 Singapore

Tel: +65 6812 7500
Fax: +65 6812 7510